SCHEMBL5043424

SCHEMBL5043424

CCCCCCSc1nc(C)cc(CN2CCCN(C(C)=O)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.48
ALDH1A1 P00352 3/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 2/20 0.36
ALPL P05186 1/20 0.36
GPR84 Q9NQS5 1/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
MAPT P10636 1/20 0.35
GBA1 P04062 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045769 0.86 SMN1; SMN2 (0.43) ALDH1A1HPGDHSD17B10HRH3L3MBTL1
SCHEMBL5047348 0.85 SMN1; SMN2 (0.43) ALDH1A1HPGDHSD17B10HRH3L3MBTL1
SCHEMBL5049973 0.85 SMN1; SMN2 (0.43) ALDH1A1HPGDHSD17B10HRH3L3MBTL1
SCHEMBL5050013 0.84 SMN1; SMN2 (0.39) ALDH1A1HPGDSMN1; SMN2HTTGPR84
SCHEMBL5049995 0.83 SMN1; SMN2 (0.43) THRBALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL5046114 0.82 NCF1 (0.42) ALDH1A1KMT2ASMN1; SMN2HTTGAA
SCHEMBL5046236 0.79 HSD17B10 (0.46) THRBALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5047449 0.79 SPHK1 (0.40) THRBALDH1A1HSD17B10L3MBTL1MEN1
SCHEMBL5042209 0.79 HSD17B10 (0.46) THRBALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5047535 0.78 BCHE (0.51) ALDH1A1HPGDHSD17B10L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US claimed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US claimed
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 THRB 434/4885ALDH1A1 3230/4885HPGD 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.